论文部分内容阅读
目的:研究分析利妥昔单抗联合化疗治疗弥漫型大B细胞淋巴瘤的临床效果。方法:选2015年2月至2016年2月收治的弥漫型大B细胞淋巴瘤患者96例。均分两组。对照组患者单纯采取化疗治疗措施,观察组则在使用利妥昔单抗基础上联合予以治疗。对比两组患者临床疗效、药物不良反应以及3年生存率。结果:观察组患者治疗疗程结束后总效率为77.1%,对照组患者总有效率为56.3%,两组患者总有效率差异显著(P<0.05);对比两组患者1-3年的进展生存率和总生存率,观察组均高于对照组,数据符合统计学意义(P<0.05);而对比两组患者治疗期间不良反应发生情况的时候,数据并不具有统计学意义(P>0.05)。结论:弥漫型大B细胞淋巴瘤患者在采取临床化疗治疗措施的同时,联合利妥昔单抗予以治疗,将显著提高患者近期临床治疗效率,延长患者生存期限,且还不会增加患者的不良反应,临床应用价值较高。
Objective: To study the clinical effect of rituximab combined with chemotherapy in the treatment of diffuse large B cell lymphoma. Methods: A total of 96 patients with diffuse large B-cell lymphoma from February 2015 to February 2016 were selected. Divided into two groups. Patients in the control group were treated with chemotherapy alone, while those in the observation group were treated with rituximab. The clinical efficacy, adverse drug reactions and 3-year survival rate were compared between the two groups. Results: The total effective rate was 77.1% in the observation group and 56.3% in the control group, and the total effective rate was significantly different between the two groups (P <0.05). Comparing the two groups of patients with 1-3 years of progressive survival Rate and overall survival rate in the observation group were higher than those in the control group, the data were statistically significant (P <0.05); while the data of the two groups were not statistically significant when compared with the control group (P> 0.05 ). Conclusions: Patients with diffuse large B-cell lymphoma treated with combination of rituximab and clinical chemotherapy should significantly improve the short-term clinical efficacy, prolong the survival of patients and not increase the patients’ Response, clinical application of higher value.